Key facts
- Fibroheal Woundcare’s last known valuation is $5.2M (Dec 2024).
- It has raised $14.1M; the latest was Later Stage VC ($12.0M) in Dec 2024.
- Notable investors include BIRAC, Telama Investments, Abishek Vijaykumar, Centre for Cellular And Molecular Platforms, Joseph James — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Fibroheal Woundcare
- ·The full record, as it builds
Funding rounds
No funding rounds for Fibroheal Woundcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fibroheal Woundcare
Developer of active wound care products intended to heal acute and chronic wounds or non-healing wounds through indigenously developed intellectual property-protected technology. The company uses the biomaterial property of silk and silk protein to provide wound care management for acute, chronic, surgical and traumatic wounds as well as address post-operative dressings, enabling wound care professionals in both institutional and customer segments to have access to advanced, affordable and effective wound care services for all types and stages of wounds.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2017
- Employees
- 72
- Website
- fibroheal.com/
- Ownership
- Privately Held (backing)
Fibroheal Woundcare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fibroheal Woundcare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fibroheal Woundcare in its N-PORT filings yet. We sweep new filings monthly.